Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23170323 | 0.91 | MAPT (0.37) | MAPTKDM4EHSD17B10KMT2A | |
| SCHEMBL29812874 | 0.91 | MAPT (0.37) | MAPTKDM4EHSD17B10KMT2A | |
| SCHEMBL23147888 | 0.90 | KDM4E (0.33) | ALDH1A1MAPTKDM4EHTTHSD17B10 | |
| SCHEMBL24113246 | 0.86 | CTSL (0.38) | MAPTHTTKMT2A | |
| SCHEMBL30310695 | 0.86 | CTSL (0.38) | MAPTHTTKMT2A | |
| SCHEMBL24996986 | 0.82 | ALDH1A1 (0.38) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL24997201 | 0.80 | AXL (0.38) | ALDH1A1MAPTKDM4EHTTHSD17B10 | |
| SCHEMBL24113139 | 0.79 | CA1 (0.39) | MAPTHTTHPGDCA12CA1 | |
| SCHEMBL22620771 | 0.79 | MAPT (0.33) | ALDH1A1MAPTKDM4EHPGDCA12 | |
| SCHEMBL30008568 | 0.79 | CA1 (0.39) | MAPTHTTHPGDCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040909-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040909-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | IDO1, IDO2, INMT | ALDH1A1 477/4885MAPT 960/4885KDM4E 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.